Kancera strengthens patent rights related to ROR antibody therapy

Kancera announces that it has signed an agreement with Bioinvent to acquire BioInvent ́s rights to the patent application WO 2011/079902, covering therapeutic antibodies directed against the ROR receptor for treatment of cancer.

Read More

Kancera to present at the 2012 BIO International Convention

Kancera AB today announced that Dr. Thomas Olin, CEO of Kancera, will present the company at the 2012 BIO International Convention taking place June 18-21 in Boston, USA.

Read More

Professor Carl-Henrik Heldin strengthens the Board of Kancera

Kancera announces that Professor Carl-Henrik Heldin has been elected to Kancera ́s Board at the company's annual general meeting May 28.

Read More

Interim Report for Kancera AB (publ) Q1 2012

January 1 - March 31, 2012 All figures relate to the Kancera Group unless otherwise specified. The 2011 comparison figures for operating income and income after financial items were affected by the release of negative goodwill of SEK 7m...

Read More

Kancera´s ROR inhibitors are active against Fludarabine resistant leukemia

Kancera's inhibitors of ROR1 show an effect on leukemia cells from patients for whom standard therapy is not currently working. Kancera's partner and co-founder Professor Håkan Mellstedt and his research group at the Karolinska University Hospital conducted the studies.

Read More

A new diagnostic tool increases the value of Kancera´s ROR technology

Kancera has, in collaboration with Professor Håkan Mellstedt's research group at the Karolinska Institute, developed antibodies that permit the development of a diagnostic tool to identify patient response to treatment using Kancera's ROR inhibitors.

Read More

Data indicate broad utility of Kancera’s PFKFB3 inhibitors.

Kancera AB (publ), Sweden, has demonstrated effect with their PFKFB3 inhibitors in cells from three different types of solid tumors. In addition to the previously reported enhancement on effects off cisplatin's effect ion gastric cancer cells, the company has...

Read More

Kancera presents at Boston seminar April 27th, 2012.

Kancera presents the company and its projects at Cambridge Innovation Center in Boston (MA) USA on Friday April 27th, 2012. The overall topic of the seminar is "Lead Generation and Structure-Based Drug Design in Cancer Research".

Read More

Kanceras ROR project has been selected for presentation at the ASCO annual meeting in Chicago.

Kancera announced today that American Society of Clinical Oncology has selected Kancera's ROR project for presentation at this year's major conference in Chicago on June 1-5, 2012.The scientific results will be presented by Professor Håkan Mellstedt in a paper...

Read More

Kancera’s ROR inhibitors show superior efficacy in 3D pancreatic tumor model.

Kancera today announced that its ROR inhibitor show effect in an advanced and challenging human pancreatic cancer model. In the model, the Kancera compounds show superior efficacy compared to gemcitabine, today's most commonly used treatment for pancreatic cancer. The...

Read More